Gapping up
News:
- XERS +23% (FDA approves Recorlev; plans commercial launch in 1Q22)
- LXRX +5.8% (submits NDA to FDA seeking approval for sotagliflozin for type 2 diabetes)
- MCFT +1.2% (Coliseum Capital Mgmt discloses 5.8% stake)
- FTCV +1% (lowers eToro valuation)
- AMD +0.5% (AMD and XLNX push back timing of acquisition close into 1Q22)
Analyst comments:
- APLS +1% (added Needham Conviction list and reiterated Buy rating)